BRIEF-FDA grants priority status to Gilead's HIV treatments
August 10, 2017 at 16:21 PM EDT
* Gilead announces U.S. fda priority review designation for fixed-dose combination of bictegravir, emtricitabine and tenofovir alafenamide for treatment of HIV
